Back to News
Market Impact: 0.2
Theriva Biologics Consensus Price Target Raised 60% to $4.08
Source: Nasdaq
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Fintel-compiled aggregate analyst price targets for Theriva Biologics were revised to $4.08 per share, up 60.00% from the prior estimate of $2.55 dated October 20, 2026. The article text is truncated and provides no further details about the estimates or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
TOVX0.35
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Why is Apple stock falling afterhours today?
- Mizuho lowers Lumentum stock price target on Marvell acquisition